3SBio Will Pay $50 Million Upfront for China Rights to Two TLC Products
publication date: Mar 4, 2019
3SBio of Shenyang will pay $50 million upfront, plus milestones, for China rights to commercialize two liposomal products developed by Taiwan Liposome. TLC used its NanoX™ platform to develop the candidates for oncology and severe infectious disease. 3SBio and TLC will cooperate to obtain regulatory approvals in China, while TLC will manufacture the products. According to TLC, its NanoX platform uses a lipid delivery system to lower toxicity, reduce the frequency of dosing, and distribute APIs more evenly. More details....
Stock Symbols: (HK: 1530) (NSDQ: TLC, TWO: 4152)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.